Venus Remedies has achieved a major milestone after receiving Marketing Authorization from the Saudi Food and Drug Authority for its specialty oncology therapy Plerixafor. The approval marks the company’s first-ever global authorization for the drug and strengthens its growing focus on complex injectable therapies in regulated international markets.
The approved product, Plerixafor 24mg/1.2ml, is used in combination with granulocyte-colony stimulating factor (G-CSF) for hematopoietic stem cell mobilization in patients undergoing autologous transplantation. The therapy is widely used in haemato-oncology, particularly for individuals suffering from multiple myeloma and non-Hodgkin lymphoma.
According to the company, the approval represents a strategic transition from conventional high-volume injectable products toward specialized, higher-value therapies in oncology and critical care.
Speaking on the development, Saransh Chaudhary said Saudi Arabia was chosen as the launch market due to its rapidly expanding oncology and transplant ecosystem. He highlighted that the Kingdom has one of the largest pharmaceutical markets in the GCC region and increasing demand for advanced transplant-related therapies.
He added that Plerixafor fits perfectly within the company’s strategy of building a differentiated portfolio of specialty injectables where clinical complexity and stringent regulatory requirements create sustainable long-term opportunities.
The Saudi pharmaceutical market is expected to witness steady expansion over the coming years, supported by healthcare reforms and increased investment under Vision 2030. Rising cancer cases and growing stem cell transplantation infrastructure are also driving demand for advanced oncology treatments across the Gulf region.
Aditi K. Chaudhary stated that the SFDA approval will help the company strengthen hospital partnerships and accelerate future specialty oncology launches across GCC countries. She emphasized that regulatory approvals and commercial expansion are closely connected in strategic markets such as Saudi Arabia.
With this approval, Venus Remedies plans to commercialize Plerixafor through its existing international distribution network, primarily targeting tertiary oncology and transplant centers across Saudi Arabia.
